Immune deficiency due to SARS-CoV-2 infection in a child with GATA2-mutated AML: A case report

SARS-CoV-2感染导致GATA2突变型急性髓系白血病患儿免疫缺陷:病例报告

阅读:1

Abstract

RATIONALE: Mutations in the guanine-adenine-thymine-adenine 2 (GATA2) gene can lead to immunodeficiency and haematological diseases, including acute myeloid leukaemia (AML). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported to impair immune function, but its effects on GATA2 mutation carriers remain unclear. This study reports a rare case of persistent immunodeficiency in a child with AML and GATA2 mutation after SARS-CoV-2 infection, emphasizing the role of viral infection in immune dysfunction in such patients. PATIENT CONCERNS: A 9-year-old AML patient developed fever, cough, persistent immunodeficiency, and recurrent severe infections after SARS-CoV-2 infection in haematological remission. DIAGNOSES: The patient was diagnosed with AML-M2 with germline GATA2 mutation. After chemotherapy, he achieved haematological remission. After SARS-CoV-2 infection, he showed significant immunodeficiency manifestations and recurrent infections. INTERVENTIONS: The patient received combined chemotherapy based on CALSIII-AML18 and achieved haematological remission. After SARS-CoV-2 infection, comprehensive treatments - for example, antiviral (Paxlovid), antibacterial, antifungal, and hormonal therapies - were used to support immune function. The patient completed HLA matching for allogeneic hematopoietic stem cell transplantation and is scheduled to undergo transplantation. OUTCOMES: Despite various immune support treatments after SARS-CoV-2 infection, the patient still had persistent immune deficiency and recurrent infections (e.g., pneumonia and hepatitis B). The patient is currently stable and waiting for hematopoietic stem cell transplantation. LESSONS: For AML patients with GATA2 mutation who achieve remission, SARS-CoV-2 infection may still trigger severe and persistent immunodeficiency, leading to serious infections and affecting prognosis. Therefore, early identification of GATA2 mutations and early implementation of hematopoietic stem cell transplantation are key to improving prognoses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。